MX2021003490A - Terapia combinada para el tratamiento de melanoma uveal. - Google Patents
Terapia combinada para el tratamiento de melanoma uveal.Info
- Publication number
- MX2021003490A MX2021003490A MX2021003490A MX2021003490A MX2021003490A MX 2021003490 A MX2021003490 A MX 2021003490A MX 2021003490 A MX2021003490 A MX 2021003490A MX 2021003490 A MX2021003490 A MX 2021003490A MX 2021003490 A MX2021003490 A MX 2021003490A
- Authority
- MX
- Mexico
- Prior art keywords
- uveal melanoma
- pac
- uveal
- drug combinations
- synergistic
- Prior art date
Links
- 201000005969 Uveal melanoma Diseases 0.000 title abstract 6
- 238000011282 treatment Methods 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 abstract 3
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 abstract 3
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 abstract 3
- 229960005552 PAC-1 Drugs 0.000 abstract 3
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 abstract 3
- 239000000890 drug combination Substances 0.000 abstract 3
- 230000002195 synergetic effect Effects 0.000 abstract 3
- 229950000521 entrectinib Drugs 0.000 abstract 2
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 abstract 2
- 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 abstract 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 abstract 1
- 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 abstract 1
- 101001072407 Homo sapiens Guanine nucleotide-binding protein subunit alpha-11 Proteins 0.000 abstract 1
- 230000004611 cancer cell death Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000030381 cutaneous melanoma Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 201000003708 skin melanoma Diseases 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 238000011301 standard therapy Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Combinaciones sinérgicas de fármacos con el PAC-1 de molécula pequeña contra melanoma uveal o cutáneo. Actualmente no existen tratamientos farmacológicos dirigidos para las mutaciones asociadas con melanoma uveal. A pesar de la radiación primaria o terapia quirúrgica, hasta un 50% de los pacientes eventualmente desarrollan enfermedad metastásica, para la que no hay terapia o tratamiento estándar que demuestre que mejora la sobrevivencia general. Las combinaciones de fármacos con PAC-1 permiten el uso de dosis menores de este compuesto que producen la muerte de células cancerosas en melanoma uveal. Las combinaciones de fármacos de PAC-1 con el inhibidor de quinasa entrectinib han demostrado un efecto sinérgico contra las líneas celulares de melanoma uveal. Específicamente, PAC-1 y entrectinib son sinérgicos contra las líneas celulares de melanoma uveal silvestres y mutantes (por ejemplo GNAQ y GNA11).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742063P | 2018-10-05 | 2018-10-05 | |
| PCT/US2019/054500 WO2020072774A1 (en) | 2018-10-05 | 2019-10-03 | Combination therapy for the treatment of uveal melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003490A true MX2021003490A (es) | 2021-06-18 |
Family
ID=70055373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003490A MX2021003490A (es) | 2018-10-05 | 2019-10-03 | Terapia combinada para el tratamiento de melanoma uveal. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220000862A1 (es) |
| EP (1) | EP3852744A4 (es) |
| JP (1) | JP2022504184A (es) |
| KR (1) | KR20210084442A (es) |
| CN (1) | CN113329749A (es) |
| AU (1) | AU2019354771A1 (es) |
| CA (1) | CA3114385A1 (es) |
| IL (1) | IL281997A (es) |
| MX (1) | MX2021003490A (es) |
| SG (1) | SG11202102485TA (es) |
| WO (1) | WO2020072774A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230416838A1 (en) * | 2020-11-16 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
| CN113318230B (zh) * | 2021-06-11 | 2022-08-26 | 上海交通大学医学院附属第九人民医院 | Optineurin在眼部黑色素瘤诊治中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014MN01945A (es) * | 2012-03-06 | 2015-07-10 | Univ Illinois | |
| EP3302478B1 (en) * | 2015-06-05 | 2021-11-17 | The Board of Trustees of the University of Illinois | Pac-1 combination therapy |
| KR20180096621A (ko) * | 2015-12-18 | 2018-08-29 | 이그니타, 인코포레이티드 | 암의 치료용 조합물 |
| US11932870B2 (en) * | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| JOP20190213A1 (ar) * | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JP7349155B2 (ja) * | 2017-11-17 | 2023-09-22 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ | 二元的なｍｅｋシグナル伝達の低減によるがん治療 |
-
2019
- 2019-10-03 KR KR1020217009896A patent/KR20210084442A/ko unknown
- 2019-10-03 SG SG11202102485TA patent/SG11202102485TA/en unknown
- 2019-10-03 US US17/281,453 patent/US20220000862A1/en active Pending
- 2019-10-03 JP JP2021518475A patent/JP2022504184A/ja active Pending
- 2019-10-03 WO PCT/US2019/054500 patent/WO2020072774A1/en unknown
- 2019-10-03 CN CN201980064553.4A patent/CN113329749A/zh active Pending
- 2019-10-03 MX MX2021003490A patent/MX2021003490A/es unknown
- 2019-10-03 AU AU2019354771A patent/AU2019354771A1/en active Pending
- 2019-10-03 CA CA3114385A patent/CA3114385A1/en active Pending
- 2019-10-03 EP EP19869986.0A patent/EP3852744A4/en active Pending
-
2021
- 2021-03-24 IL IL281997A patent/IL281997A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022504184A (ja) | 2022-01-13 |
| AU2019354771A1 (en) | 2021-04-01 |
| EP3852744A1 (en) | 2021-07-28 |
| EP3852744A4 (en) | 2022-06-08 |
| SG11202102485TA (en) | 2021-04-29 |
| WO2020072774A1 (en) | 2020-04-09 |
| US20220000862A1 (en) | 2022-01-06 |
| CA3114385A1 (en) | 2020-04-09 |
| CN113329749A (zh) | 2021-08-31 |
| IL281997A (en) | 2021-05-31 |
| KR20210084442A (ko) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008777A (es) | Inmunoterapias relacionadas con el microbioma. | |
| BR112019000598A2 (pt) | rna para terapia de câncer | |
| MX2020009773A (es) | Terapia de combinacion. | |
| BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
| BRPI0507039A8 (pt) | composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| ECSP055911A (es) | Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| PH12020551851A1 (en) | Treatment of cancers having driving oncogenic mutations | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2021003490A (es) | Terapia combinada para el tratamiento de melanoma uveal. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| ZA202301066B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| BR112022010319A2 (pt) | Uso de bi853520 no tratamento de câncer | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| BR0313470A (pt) | Combinações terapêuticas de inibidores erbb quinase e terapias antineoplásicas | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| WO2015035410A8 (en) | Cancer therapy | |
| MX2023001823A (es) | Terapia de combinacion. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. |